Spyre Therapeutics, Inc. (NASDAQ:SYRE) Shares Acquired by Northern Trust Corp

Northern Trust Corp grew its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 11.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 348,983 shares of the company’s stock after acquiring an additional 34,693 shares during the quarter. Northern Trust Corp owned 0.68% of Spyre Therapeutics worth $8,124,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the business. FMR LLC raised its position in Spyre Therapeutics by 15.4% during the fourth quarter. FMR LLC now owns 8,801,266 shares of the company’s stock valued at $204,893,000 after acquiring an additional 1,177,385 shares in the last quarter. Vanguard Group Inc. raised its position in Spyre Therapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 2,846,473 shares of the company’s stock valued at $66,266,000 after acquiring an additional 330,553 shares in the last quarter. Wellington Management Group LLP raised its position in Spyre Therapeutics by 6.5% during the fourth quarter. Wellington Management Group LLP now owns 1,604,508 shares of the company’s stock valued at $37,353,000 after acquiring an additional 97,308 shares in the last quarter. Pictet Asset Management Holding SA raised its position in Spyre Therapeutics by 32.3% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,092,124 shares of the company’s stock valued at $25,425,000 after acquiring an additional 266,418 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Spyre Therapeutics by 8.4% during the fourth quarter. Geode Capital Management LLC now owns 966,129 shares of the company’s stock valued at $22,498,000 after acquiring an additional 75,081 shares in the last quarter. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Stock Up 4.4%

NASDAQ SYRE opened at $15.18 on Monday. Spyre Therapeutics, Inc. has a fifty-two week low of $10.91 and a fifty-two week high of $40.26. The stock has a market cap of $914.99 million, a price-to-earnings ratio of -2.03 and a beta of 2.78. The business has a fifty day moving average of $14.92 and a 200-day moving average of $21.30.

Spyre Therapeutics (NASDAQ:SYRE) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.02. As a group, analysts anticipate that Spyre Therapeutics, Inc. will post -4.46 EPS for the current year.

Analysts Set New Price Targets

SYRE has been the subject of a number of recent analyst reports. Wolfe Research initiated coverage on Spyre Therapeutics in a research report on Tuesday, March 18th. They issued an “outperform” rating and a $27.00 price objective for the company. The Goldman Sachs Group upgraded Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 18th. Leerink Partnrs upgraded Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 8th. Leerink Partners started coverage on Spyre Therapeutics in a research report on Tuesday, April 8th. They set an “outperform” rating and a $45.00 price target for the company. Finally, Wedbush reiterated an “outperform” rating and set a $65.00 price target on shares of Spyre Therapeutics in a research report on Monday, May 5th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $53.40.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).